Effects of Evolocumab on Carotid Intima-Media Thickness and Clinical Parameters in Patients Taking a Statin

Effects of Evolocumab on Carotid Intima-Media Thickness and Clinical Parameters in Patients Taking a Statin

We determined the effects of evolocumab, a fully human monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9, on carotid intima-media thickness (IMT) and the factors associated with the change in carotid IMT in patients taking a statin. The change in carotid mean and maximum IM...

Full description

Bibliographic Details
Main Authors:	Keiji Hirai, Shigeki Imamura, Aizan Hirai, Susumu Ookawara, Yoshiyuki Morishita
Format:	Article
Language:	English
Published:	MDPI AG 2020-07-01
Series:	Journal of Clinical Medicine
Subjects:	atherosclerosis carotid intima-media thickness evolocumab proprotein convertase subtilisin/kexin type 9
Online Access:	https://www.mdpi.com/2077-0383/9/7/2256

Similar Items

Effect of Evolocumab on Vulnerable Coronary Plaques: A Serial Coronary Computed Tomography Angiography Study
by: Keiji Hirai, et al.
Published: (2020-10-01)

Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy
by: Zhenxian Li, et al.
Published: (2023-05-01)

Effect of Evolocumab on Lipoprotein(a) and PCSK9 in Healthy Individuals with Elevated Lipoprotein(a) Level
by: Olga Afanasieva, et al.
Published: (2020-10-01)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
by: Huang CC, et al.
Published: (2019-10-01)

Efficacy of Evolocumab in Patients with Hypercholesterolemia
by: Xuan Jin, et al.
Published: (2020-12-01)

Effects of Evolocumab Added to Moderate-Intensity Statin Therapy in Chinese Patients With Acute Coronary Syndrome: The EMSIACS Trial Study Protocol
by: Jing Gao, et al.
Published: (2021-11-01)

Effect of evolocumab on the progression of intraplaque neovascularization of the carotid based on contrast-enhanced ultrasonography (EPIC study): A prospective single-arm, open-label study
by: Ju Chen, et al.
Published: (2023-01-01)

Application of evolocumab in patients with coronary heart disease complicated with mild renal insufficiency
by: Zhang Yu, Wu Bin, Feng Jiaxu, Wang Rutao, Yuan Ming
Published: (2023-10-01)

Cross-country comparison in the evaluation of evolocumab by health technology assessment agencies in England, Canada, and Australia
by: Swaroop Varghese, et al.
Published: (2019-01-01)

Effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with familial hypercholesterolemia. Our experience in implementing the drug program of the Polish National Health Fund
by: Beata Bobrowska, et al.
Published: (2022-08-01)

Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report
by: Yuki Awanami, et al.
Published: (2017-07-01)

PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
by: Yehuda Handelsman, et al.
Published: (2018-07-01)

Treatment of atherogenic dyslipidemia: modern principles and new possibilities
by: M. G Bubnova
Published: (2017-06-01)

Levels of proprotein convertase subtilisin/kexin type 9 in patients with acute myocardial infarction
by: A. D. Gimadeeva, et al.
Published: (2020-03-01)

PCSK9 inhibition fails to alter hepatic LDLR, circulating cholesterol, and atherosclerosis in the absence of ApoE[S]
by: Brandon Ason, et al.
Published: (2014-11-01)

Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet’s disease
by: Rabia Aydogan Baykara, et al.
Published: (2022-07-01)

ASSOCIATION OF POLYMORPHISM IN PCSK9 GENE WITH LIPID PR OFILE IN RUSSIAN POPULATION
by: K. S. Astrakova, et al.
Published: (2016-06-01)

Functional analysis of sites within PCSK9 responsible for hypercholesterolemias⃞
by: Shilpa Pandit, et al.
Published: (2008-06-01)

Evolocumab, a PCSK9‐Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living With HIV and People With Dyslipidemia
by: Thorsten M. Leucker, et al.
Published: (2020-07-01)

Effect of evolocumab on cholesterol synthesis and absorption[S]
by: Matthew Peach, et al.
Published: (2016-12-01)

Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[S]
by: Susan Kühnast, et al.
Published: (2014-10-01)

Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians
by: Terrence L Trentman, et al.
Published: (2016-01-01)

Real-World Insights into Evolocumab Use in Patients with Hyperlipidemia Across Five Countries: Analysis from the ZERBINI Study
by: Milan Gupta, et al.
Published: (2023-10-01)

Proprotein convertase subtilisin/kexin type 9 inhibitors: prospects for cholesterol-lowering therapy in type 2 diabetes
by: V.A. Serhiyenko, et al.
Published: (2023-03-01)

The circulating furin-cleaved/mature PCSK9 ratio has a potential prognostic significance in statin-naïve patients with acute ST elevation myocardial infarction
by: Jun Sawaguchi, et al.
Published: (2022-12-01)

Relationship Between Low‐Density Lipoprotein Cholesterol and Lipoprotein(a) Lowering in Response to PCSK9 Inhibition With Evolocumab
by: Michael D. Shapiro, et al.
Published: (2019-02-01)

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role[S]
by: Frederick J. Raal, et al.
Published: (2016-06-01)

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

The rs508487, rs236911, and rs236918 Genetic Variants of the Proprotein Convertase Subtilisin–Kexin Type 7 (<i>PCSK7</i>) Gene Are Associated with Acute Coronary Syndrome and with Plasma Concentrations of HDL-Cholesterol and Triglycerides
by: Gilberto Vargas-Alarcón, et al.
Published: (2021-06-01)

ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
by: K. S. Benimetskaya, et al.
Published: (2019-03-01)

PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis
by: Qianyun Guo, et al.
Published: (2020-09-01)

Physical activity to reduce PCSK9 levels
by: Amedeo Tirandi, et al.
Published: (2022-08-01)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
by: Jia Peng, et al.
Published: (2021-02-01)

Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells[S]
by: Aiqin Cao, et al.
Published: (2011-03-01)

Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
by: Yi Luo, et al.
Published: (2009-08-01)

Use of PCSK9 Inhibitors in Solid Organ Transplantation Recipients
by: Bruce A. Warden, PharmD, et al.
Published: (2020-03-01)

The association of the PCSK9 rs562556 polymorphism with serum lipids level: a meta-analysis
by: Junlan Chuan, et al.
Published: (2019-04-01)

Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells
by: Ting‐Hsing Chao, et al.
Published: (2016-05-01)

Independent association of PCSK9 with platelet reactivity in subjects without statin or antiplatelet agents
by: Shuai Wang, et al.
Published: (2022-10-01)

The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk
by: Natalie Schellack, et al.
Published: (2016-01-01)